Abstract
Background A major systemic lupus erythematosus (SLE) susceptibility locus lies within a common inversion polymorphism region (encompassing 3.8-4.5 Mb) located at 8p23. Initially implicated genes included FAM167A-BLK and XKR6, of which BLK received major attention due to its known role in B-cell biology. Recently, additional SLE risk carried in non-inverted background was also reported. Objective and methods In this case-control study, we further investigated the 'extended' 8p23 locus (~4 Mb) where we observed multiple SLE signals and assessed these signals for their relation to the inversion affecting this region. The study involved a North American discovery data set (~1200 subjects) and a replication data set (>10 000 subjects) comprising European-descent individuals. Results Meta-analysis of 8p23 SNPs, with p<0.05 in both data sets, identified 51 genome-wide significant SNPs (p<5.0×10-8). While most of these SNPs were related to previously implicated signals (XKR6-FAM167ABLK subregion), our results also revealed two 'new' SLE signals, including SGK223-CLDN23-MFHAS1 (6.06×10-9≤meta p≤4.88×10-8) and CTSB (meta p=4.87×10-8) subregions that are located >2 Mb upstream and ~0.3 Mb downstream from previously reported signals. Functional assessment of relevant SNPs indicated putative cis-effects on the expression of various genes at 8p23. Additional analyses in discovery sample, where the inversion genotypes were inferred, replicated the association of non-inverted status with SLE risk and suggested that a number of SLE risk alleles are predominantly carried in non-inverted background. Conclusions Our results implicate multiple (known+novel) SLE signals/genes at the extended 8p23 locus, beyond previously reported signals/genes, and suggest that this broad locus contributes to SLE risk through the effects of multiple genes/pathways.
Original language | English (US) |
---|---|
Pages (from-to) | 381-389 |
Number of pages | 9 |
Journal | Journal of medical genetics |
Volume | 54 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2017 |
Funding
This work was supported by grants from the US NIH (HL092397, HL088648, AR057028, AR046588, AR057338, HD066139, AR002138, AR030692, AR064464 and TR000150) and by grants from Wellcome Trust (Ref 085492) and Arthritis Research UK (Ref 19289).
ASJC Scopus subject areas
- Genetics(clinical)
- Genetics